BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1767 related articles for article (PubMed ID: 17524578)

  • 1. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of heterogeneous nucleation on the surface crystallization of guaifenesin from melt extrudates containing Eudragit L10055 or Acryl-EZE.
    Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Eur J Pharm Biopharm; 2010 May; 75(1):71-8. PubMed ID: 19995604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aqueous film coating to reduce recrystallization of guaifenesin from hot-melt extruded acrylic matrices.
    Bruce CD; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Drug Dev Ind Pharm; 2010 Feb; 36(2):218-26. PubMed ID: 19877992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The manufacture and characterisation of hot-melt extruded enteric tablets.
    Andrews GP; Jones DS; Diak OA; McCoy CP; Watts AB; McGinity JW
    Eur J Pharm Biopharm; 2008 May; 69(1):264-73. PubMed ID: 18164604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of melt extruded enteric matrix pellets.
    Schilling SU; Shah NH; Waseem Malick A; McGinity JW
    Eur J Pharm Biopharm; 2010 Feb; 74(2):352-61. PubMed ID: 19782133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citric acid as a solid-state plasticizer for Eudragit RS PO.
    Schilling SU; Shah NH; Malick AW; Infeld MH; McGinity JW
    J Pharm Pharmacol; 2007 Nov; 59(11):1493-500. PubMed ID: 17976259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers.
    Zhu Y; Shah NH; Malick AW; Infeld MH; McGinity JW
    Drug Dev Ind Pharm; 2006 Jun; 32(5):569-83. PubMed ID: 16720412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit S100:L100 dispersion.
    Bando H; McGinity JW
    Int J Pharm; 2006 Oct; 323(1-2):11-7. PubMed ID: 16815652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of hot-melt extruded tablet formulations for the colonic delivery of 5-aminosalicylic acid.
    Bruce LD; Shah NH; Malick AW; Infeld MH; McGinity JW
    Eur J Pharm Biopharm; 2005 Jan; 59(1):85-97. PubMed ID: 15567305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
    Andrews GP; AbuDiak OA; Jones DS
    J Pharm Sci; 2010 Mar; 99(3):1322-35. PubMed ID: 19798757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of extended release Kollidon SR mini-matrices prepared by hot-melt extrusion.
    Ozgüney I; Shuwisitkul D; Bodmeier R
    Eur J Pharm Biopharm; 2009 Sep; 73(1):140-5. PubMed ID: 19406237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.
    Albers J; Alles R; Matthée K; Knop K; Nahrup JS; Kleinebudde P
    Eur J Pharm Biopharm; 2009 Feb; 71(2):387-94. PubMed ID: 18951978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of plasticizer level on the drug release from sustained release film coated and hot-melt extruded dosage forms.
    Zhu Y; Mehta KA; McGinity JW
    Pharm Dev Technol; 2006; 11(3):285-94. PubMed ID: 16895839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions.
    DiNunzio JC; Brough C; Miller DA; Williams RO; McGinity JW
    Eur J Pharm Sci; 2010 Jun; 40(3):179-87. PubMed ID: 20230894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and stability of solid dispersions based on PEG/polymer blends.
    Bley H; Fussnegger B; Bodmeier R
    Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability.
    Ghebremeskel AN; Vemavarapu C; Lodaya M
    Int J Pharm; 2007 Jan; 328(2):119-29. PubMed ID: 16968659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of plasticizer type and level on the properties of Eudragit S100 matrix pellets prepared by hot-melt extrusion.
    Schilling SU; Lirola HL; Shah NH; Waseem Malick A; McGinity JW
    J Microencapsul; 2010; 27(6):521-32. PubMed ID: 20575612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical properties of enteric films prepared from aqueous dispersions and organic solutions.
    Bando H; McGinity JW
    Int J Pharm; 2006 Apr; 313(1-2):43-8. PubMed ID: 16487672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.